



## ASX Announcement

17 March 2023

### **Avecho to present at NWR Virtual Healthcare Conference**

**Melbourne, Australia, 17 March 2023** - [Avecho Biotechnology Limited](#) (ASX:AVE, "Avecho", or "the Company") is pleased to announce that it will present at the NWR Virtual Healthcare Conference.

CEO, Dr Paul Gavin, will present at 1:00pm AEDT on Tuesday 21 March 2023.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link:

[https://us02web.zoom.us/webinar/register/WN\\_arGaJf4JT0eeq7dsplNzeg](https://us02web.zoom.us/webinar/register/WN_arGaJf4JT0eeq7dsplNzeg)

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company's website and social media channels.

Questions can be submitted on the day or sent in advance to [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

For more information please visit: <https://nwrcommunications.com/healthconf>

#### **For enquiries, please contact**

Dr Paul Gavin  
Chief Executive Officer  
+61 3 9002 5000

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

#### **About Avecho**

Avecho Biotechnology Limited (ASX: AVE) develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called TPM® (Tocopherol Phosphate Mixture). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market, including the recently announced application of TPM® to cannabinoids. The Company is also developing TPM® to enhance feed efficiency and health of livestock.

See more here - [avecho.com.au](https://avecho.com.au)